Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects
Reilly, Paul A., PhD, van Ryn, Joanne, PhD, Grottke, Oliver, MD, PhD, Glund, Stephan, PhD, Stangier, Joachim, PhD
Published in The American journal of medicine (01.11.2016)
Published in The American journal of medicine (01.11.2016)
Get full text
Journal Article
Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers
Glund, Stephan, PhD, Stangier, Joachim, PhD, van Ryn, Joanne, PhD, Schmohl, Michael, PhD, Moschetti, Viktoria, MD, Haazen, Wouter, MD, De Smet, Marina, PhD, Gansser, Dietmar, PhD, Norris, Stephen, PhD, Lang, Benjamin, Dipl-Math oec, Reilly, Paul, PhD, Kreuzer, Jörg, MD
Published in Journal of the American College of Cardiology (05.04.2016)
Published in Journal of the American College of Cardiology (05.04.2016)
Get full text
Journal Article
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects
Reilly, Paul A., PhD, van Ryn, Joanne, PhD, Grottke, Oliver, MD, PhD, Glund, Stephan, PhD, Stangier, Joachim, PhD
Published in The American journal of emergency medicine (01.11.2016)
Published in The American journal of emergency medicine (01.11.2016)
Get full text
Journal Article